<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01189201</url>
  </required_header>
  <id_info>
    <org_study_id>1275.3</org_study_id>
    <secondary_id>2010-019211-38</secondary_id>
    <nct_id>NCT01189201</nct_id>
  </id_info>
  <brief_title>Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food</brief_title>
  <official_title>Relative Bioavailability Investigations of a 25 mg BI 10773 / 5 mg Linagliptin Fixed Dose Combination (FDC) Tablet (Formulation A1) Including the Comparison With Its Mono-components, the Comparison With a Second FDC Tablet (Formulation A3), and the Investigation of Food (an Open-label, Randomised, Single Dose, Crossover, Phase I Trial in Healthy Male and Female Volunteers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the relative bioavailability of
      BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test)
      compared to BI 10773 given in free combination with linagliptin (Treatment B, Reference),
      both in the fasting state. All 42 subjects entered are planned to be included in this
      comparison.

      The secondary objective is to investigate the relative bioavailability of BI 10773 /
      linagliptin fixed dose combination tablet after administration of a standardised high fat,
      high caloric meal (formulation A1, Treatment C, Test) compared to BI 10773 / linagliptin
      fixed dose combination in the fasting state (formulation A1,Treatment A, Reference). Of the
      42 subjects entered 18 subjects are planned to be included in this comparison.

      An additional objective is to investigate the relative bioavailability of a second
      formulation of the fixed dose combination tablet of BI 10773 / linagliptin (formulation
      A3,Treatment D, Test) compared to BI 10773 / linagliptin fixed dose combination tablet
      (formulation A1,Treatment A, Reference). Of the 42 subjects entered 24 subjects are planned
      to be included in this comparison.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empagliflozin: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of empagliflozin (empa) in plasma.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of empagliflozin (empa) in plasma.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Time from last dosing to the maximum measured concentration of linagliptin in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)</measure>
    <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the &quot;measured values&quot; show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator</measure>
    <time_frame>Drug administration until next treatment period/end-of-study examination, up to 36 days</time_frame>
    <description>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 10773/linagliptin FDC SID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium single dose ofBI 10773/linagliptin FDC (Formulation A1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773/linagliptin SID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium single dose of mono components BI 10773/linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773/linagliptin FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773/linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium single dose of BI 10773/linagliptin FDC (Formulation A3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773/linagliptin</intervention_name>
    <description>medium single dose of BI 10773/linagliptin FDC (Formulation A1)</description>
    <arm_group_label>BI 10773/linagliptin FDC SID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773/linagliptin</intervention_name>
    <description>medium single dose of BI 10773/linagliptin FDC (Formulation A3)</description>
    <arm_group_label>BI 10773/linagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773/linagliptin SID</intervention_name>
    <description>medium single dose of mono components BI 10773/linagliptin</description>
    <arm_group_label>BI 10773/linagliptin SID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773/linagliptin FDC</intervention_name>
    <description>medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal</description>
    <arm_group_label>BI 10773/linagliptin FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        healthy male and female subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1275.3.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <results_first_submitted>March 10, 2015</results_first_submitted>
  <results_first_submitted_qc>March 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 19, 2015</results_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Overall</title>
          <description>A randomised, open label, three period, crossover trial. Each subject was to receive 3 of 4 possible treatments. The treatments were
Empagliflozin plus linagliptin fixed dose combination (FDC) A1 (fasted)
Empagliflozin plus linagliptin, individual tablets (fasted)
Empagliflozin plus linagliptin FDC A1 (fed)
Empagliflozin plus linagliptin FDC A3 (fasted)
Drug administrations were separated by a washout period of at least 35 days.
A total of 42 subjects were entered into the study, all subjects were allocated to the FDC A1 (fasted) and individual tablet treatments as this was the primary objective of the study. Along with this 18 of the subjects were allocated to receive the FDC A1 (fed) treatment and other 24 subjects to the FDC A3 treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Empa/Linagliptin FDC A1(Fasted)</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rec. Empa/Linagliptin Ind.Tablet(Fasted)</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Empa/Linagliptin FDC A1 (Fed)</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Empa/Linagliptin FDC A3(Fasted)</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Overall</title>
          <description>A randomised, open label, three period, crossover trial. Each subject was to receive 3 of 4 possible treatments. The treatments were
Empagliflozin plus linagliptin fixed dose combination (FDC) A1 (fasted)
Empagliflozin plus linagliptin, individual tablets (fasted)
Empagliflozin plus linagliptin FDC A1 (fed)
Empagliflozin plus linagliptin FDC A3 (fasted)
Drug administrations were separated by a washout period of at least 35 days.
A total of 42 subjects were entered into the study, all subjects were allocated to the FDC A1 (fasted) and individual tablet treatments as this was the primary objective of the study. Along with this 18 of the subjects were allocated to receive the FDC A1 (fed) treatment and other 24 subjects to the FDC A3 treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5990" spread="21.0"/>
                    <measurement group_id="O2" value="5720" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin individual tablets (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>104.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.07</ci_lower_limit>
            <ci_upper_limit>107.80</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)</title>
        <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Area Under the Curve 0 to 72 Hours (AUC0-72)</title>
          <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264" spread="22.1"/>
                    <measurement group_id="O2" value="250" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin individual tablets (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>104.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.97</ci_lower_limit>
            <ci_upper_limit>110.09</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empagliflozin: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of empagliflozin (empa) in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of empagliflozin (empa) in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="862" spread="26.8"/>
                    <measurement group_id="O2" value="803" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin individual tablets (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>107.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.70</ci_lower_limit>
            <ci_upper_limit>114.02</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="36.4"/>
                    <measurement group_id="O2" value="7.49" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin individual tablets (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>109.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>26.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.55</ci_lower_limit>
            <ci_upper_limit>120.83</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)</title>
        <description>Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
          <group group_id="O3">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
          <group group_id="O4">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3.</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin: Time From Last Dosing to Maximum Measured Concentration (Tmax)</title>
          <description>Time from last dosing to the maximum measured concentration of empagliflozin (empa) in plasma.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.67" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.67" upper_limit="3.98"/>
                    <measurement group_id="O3" value="2.00" lower_limit="0.67" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.67" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)</title>
        <description>Time from last dosing to the maximum measured concentration of linagliptin in plasma</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
          <group group_id="O3">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
          <group group_id="O4">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3.</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Time From Last Dosing to Maximum Measured Concentration (Tmax)</title>
          <description>Time from last dosing to the maximum measured concentration of linagliptin in plasma</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.33" upper_limit="6.03"/>
                    <measurement group_id="O2" value="1.75" lower_limit="0.67" upper_limit="10.0"/>
                    <measurement group_id="O3" value="2.25" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.33" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6060" spread="20.7"/>
                    <measurement group_id="O2" value="5800" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin individual tablets (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>104.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.02</ci_lower_limit>
            <ci_upper_limit>107.61</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435" spread="26.5"/>
                    <measurement group_id="O2" value="410" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin individual tablets (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>104.64</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.23</ci_lower_limit>
            <ci_upper_limit>112.62</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6410" spread="16.0"/>
                    <measurement group_id="O2" value="5500" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A1 (fed)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>85.86</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.33</ci_lower_limit>
            <ci_upper_limit>90.64</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin Fed vs Fasted: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of empagliflozin (empa) in plasma, comparing fed with fasted.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949" spread="23.7"/>
                    <measurement group_id="O2" value="583" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A1 (fed)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>61.41</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.10</ci_lower_limit>
            <ci_upper_limit>69.71</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin Fed vs Fasted: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6330" spread="16.4"/>
                    <measurement group_id="O2" value="5400" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A1 (fed)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>85.32</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.77</ci_lower_limit>
            <ci_upper_limit>90.14</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin Fed vs Fasted: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453" spread="24.2"/>
                    <measurement group_id="O2" value="421" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A1 (fed)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>93.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.07</ci_lower_limit>
            <ci_upper_limit>102.05</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin Fed vs Fasted: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="40.0"/>
                    <measurement group_id="O2" value="6.14" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A1 (fed)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>68.48</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.59</ci_lower_limit>
            <ci_upper_limit>80.03</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)</title>
        <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin Fed vs Fasted: Area Under the Curve 0 to 72 Hours (AUC0-72)</title>
          <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275" spread="21.7"/>
                    <measurement group_id="O2" value="250" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A1 (fed)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>90.95</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.24</ci_lower_limit>
            <ci_upper_limit>98.19</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3 (FDC A3).</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5810" spread="23.1"/>
                    <measurement group_id="O2" value="5560" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A3 (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>95.64</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.19</ci_lower_limit>
            <ci_upper_limit>100.30</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of empagliflozin (empa) in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3.</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin Formulation Comparison: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of empagliflozin (empa) in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="802" spread="27.0"/>
                    <measurement group_id="O2" value="787" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A3 (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>98.04</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.95</ci_lower_limit>
            <ci_upper_limit>104.53</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3.</description>
          </group>
        </group_list>
        <measure>
          <title>Empagliflozin Formulation Comparison: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the last quantifiable drug plasma concentration.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5740" spread="23.3"/>
                    <measurement group_id="O2" value="5490" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A3 (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>95.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>9.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.17</ci_lower_limit>
            <ci_upper_limit>100.43</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
        <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3 (FDC A3).</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin Formulation Comparison: Area Under the Curve 0 to Infinity (AUC0-∞)</title>
          <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423" spread="28.3"/>
                    <measurement group_id="O2" value="393" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A3 (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>92.98</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.36</ci_lower_limit>
            <ci_upper_limit>100.09</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3 (FDC A3).</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin Formulation Comparison: Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of linagliptin in plasma.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.65" spread="32.7"/>
                    <measurement group_id="O2" value="7.93" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A3 (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>103.71</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>22.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.93</ci_lower_limit>
            <ci_upper_limit>115.74</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)</title>
        <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
        <time_frame>1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h, 72h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3 (FDC A3).</description>
          </group>
        </group_list>
        <measure>
          <title>Linagliptin Formulation Comparison: Area Under the Curve 0 to 72 Hours (AUC0-72)</title>
          <description>Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours.
In this endpoint, the “measured values“ show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities.</description>
          <population>Pharmacokinetic (PK) set: Included all subjects who were documented to have taken at least one dose of investigational treatment, who provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256" spread="22.4"/>
                    <measurement group_id="O2" value="247" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No formal testing, investigation of relative bioavailability</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Ratio calculated as empa plus linagliptin FDC A1 (fasted) divided by empa plus linagliptin FDC A3 (fasted)</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>96.36</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.78</ci_lower_limit>
            <ci_upper_limit>103.42</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator</title>
        <description>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.</description>
        <time_frame>Drug administration until next treatment period/end-of-study examination, up to 36 days</time_frame>
        <population>Treated set (TS) included all subjects who were documented to have taken at least one dose of investigational treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
          </group>
          <group group_id="O2">
            <title>Empa Plus Linagliptin Indivdual Tablets (Fasted)</title>
            <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
          </group>
          <group group_id="O3">
            <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
          </group>
          <group group_id="O4">
            <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
            <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3 (FDC A3).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator</title>
          <description>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by the Investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. Time frame for adverse event was until the end-of-study examination.</description>
          <population>Treated set (TS) included all subjects who were documented to have taken at least one dose of investigational treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment period and following washout period, up to 36 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empa Plus Linagliptin FDC A1 (Fasted)</title>
          <description>A single dose of empa 25 mg and linagliptin 5 mg fixed dose combination (FDC) tablet formulation A1 (FDC A1)</description>
        </group>
        <group group_id="E2">
          <title>Empa Plus Linagliptin Individual Tablets (Fasted)</title>
          <description>Individual tablets of empa 25 mg and linagliptin 5 mg administered together</description>
        </group>
        <group group_id="E3">
          <title>Empa Plus Linagliptin FDC A1 (Fed)</title>
          <description>A single dose of empa 25 mg and linagliptin 5 mg FDC A1 tablet given after a high-fat, high-caloric meal.</description>
        </group>
        <group group_id="E4">
          <title>Empa Plus Linagliptin FDC A3 (Fasted)</title>
          <description>A single dose of empa 25 mg and linagliptin 5 mg FDC tablet formulation A3 (FDC A3).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

